Life Sciences

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
15 June 2021

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression

Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...

Read the press release
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
24 March 2021

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical...

Read the press release
Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG
18 March 2021

Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG

Calls for genuine corporate responsibility efforts have been high on the agenda for some time, but the pandemic — and its wide-ranging impact on all organisations, including...

Read more
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
17 March 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...

Read the press release
YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders,  as well as the Inclusion of the Obese Patients in the Second Arm of the Trial
4 March 2021

YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders, as well as the Inclusion of the Obese Patients in the Second Arm of the Trial

YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative drugs using the properties of key bacterial strains...

Read the press release
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
2 March 2021

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that...

Read the press release
Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments
9 February 2021

Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments

Seventure led $10M round for new French company focusing on I/O-microbiome and provided $3M seed funding to ErVaccine, driving an increased I/O microbiome focus in fund...

Read the press release
Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why microbiota samples should be collected in all clinical trials?
26 January 2021

Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why microbiota samples should be collected in all clinical trials?

In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing...

Read more
The century of the microbiome: an exciting time for human health
26 January 2021

The century of the microbiome: an exciting time for human health

While the pandemic might have caused some disruption, microbiome research hasn’t slowed down at all, notes Isabelle de Cremoux, CEO and Managing Partner, Seventure...

Read more
‘Significant interest’: Venture capital major Seventure Partners extends €200m+ microbiome fund
13 January 2021

‘Significant interest’: Venture capital major Seventure Partners extends €200m+ microbiome fund

European life sciences investment firm Seventure Partners has extended the final close of its second microbiome innovation fund and increased focus on advances in the skin...

Read more